Secukinumab - Psoriasis

You are here : Home > Formulary Search > Secukinumab - Psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines

ICB

NICE

SPC

Restrictions / Comments :

Documentation

NICE Technology Appraisal

NICE TA350 - Secukinumab for treating moderate to severe plaque psoriasis

Evidence Review

Secukinumab for treating plaque psoriasis - Briefing paper -October 2015 .pdf

PAD Profile

ChemicalSubstance :

Secukinumab

Indication :

Psoriasis

Group Name :

Keywords :

Biologic, NICE, immunosuppressant, interleukin 17A inhibitor, DMARD, bDmard, Disease modulating, Dermatology,

Brand Names Include :

Cosentyx

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Psoriasis

Supporting Documents :

Committee Recommendations (2)

05 Nov 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed to adopt the SERMOG high-cost drugs pathway.for adiults with psoriasis

07 Oct 15 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN support the use of Secukinumab as a treatment option for treating moderate to severe plaque psoriasis in line NICE TA 350

Other Indications

Below are listed other indications that Secukinumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriasis.